Background
cancers, neuropathic pain, CIPN, pain, chronic CIPN, neurotoxic
CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY, CANCERS, ADVERSE EVENT, ONCOLOGY
Chemotherapy-induced peripheral neuropathy (CIPN) is a major adverse event affecting patients receiving treatment with neurotoxic chemotherapeutic agents including platinum, taxanes, and vinca alkaloids [Many clinical trials relating to pain treatment of CIPN have been reported. Most of these previous studies were conducted in patients with chronic CIPN after completion of chemotherapy, and only a few studies evaluated patients with CIPN during or immediately after chemotherapy. Therefore, although the management of pain caused by CIPN during the course of chemotherapy is a common problem in real-world clinical practice, there is no consensus about the management of CIPN during chemotherapy. In daily practice, chemotherapy is reduced or discontinued based on the patient’s subjective pain intensity, resulting in negative consequences for patient outcomes [When neuropathic pain medications are used during chemotherapy, the severity of CIPN specifically should be appropriately assessed in parallel with the assessment of neuropathic pain, according to the American Society of Clinical Oncology (ASCO) guideline [Several treatment options are currently available for CIPN, including selective serotonin–norepinephrine reuptake inhibitors (e.g. duloxetine), gabapentinoids (pregabalin, gabapentin), and tricyclic antidepressants (e.g. amitriptyline) [Mirogabalin besilate (henceforth referred to as mirogabalin) is an oral gabapentinoid drug with analgesic effects resulting from its ability to bind to the αIn the present study, from the perspective of real-world medical practice, we evaluated the efficacy of mirogabalin for the treatment of pain in patients who developed moderate to severe CIPN during chemotherapy with oxaliplatin or taxane for four types of solid cancers (colorectal, gastric, non-small-cell lung, and breast cancers). We also examined its influence on the completion of chemotherapy and the risk of worsening of CIPN due to underestimation of pain under mirogabalin treatment.